COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement
TuHURA and Kintara announce merger for advancing late-stage oncology pipeline with focus on personalized cancer vaccines and bi-functional ADCs. $31 million funding secured for operations till late 2025. Joint conference call scheduled for April 3, 2024 -
COMMUNIQUÉ DE PRESSE
TuHURA Biosciences, Inc. Appoints Dennis Yamashita, Ph.D., as Chief Scientific Officer and Head of Discovery Research and Early Development
TuHURA Biosciences, Inc. appoints Dr. Dennis Yamashita as Chief Scientific Officer and Head of Discovery Research and Early Development to advance novel personalized cancer vaccines and bi-functional antibody drug conjugates. Dr. Yamashita brings over 30 years of experience in R&D drug discovery and development
